<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780377</url>
  </required_header>
  <id_info>
    <org_study_id>080823</org_study_id>
    <nct_id>NCT00780377</nct_id>
  </id_info>
  <brief_title>Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients</brief_title>
  <acronym>P1A4D</acronym>
  <official_title>The Effects of Cardiac Innervation on Intra-coronary t-PA Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplant recipients do not have nerves to their hearts. This protocol tests the
      hypothesis that bradykinin mediated t-PA release in the coronary arteries will be reduced in
      heart transplant recipients compared to healthy subjects.

      This study will compare heart transplant recipients to healthy controls who are undergoing
      cardiac cath for standard of care purposes (separate protocol) and compare the coronary
      arteries to the forearm in transplant recipients (separate protocol) and healthy controls
      (separate protocol).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to perform study due to unavailable drug, then unable to partner with cath lab
  </why_stopped>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T-PA release in the coronary artery bed.</measure>
    <time_frame>Single Study Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Single study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathology for arteriolar t-PA and sympathetic neurons</measure>
    <time_frame>Single Study Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bradykinin</intervention_name>
    <description>Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.</description>
    <arm_group_label>Bradykinin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Heart transplant recipients undergoing annual cardiac catheterization who have
             participated our protocol: Characterization of brachial arterial t-PA release,
             vasodilator function, and vascular compliance and correlation with fibrinolytic
             balance, oxidative stress, and inflammation measures in heart transplant recipients
             (SCCOR Project 1, Aim 3C). (IRB # 070517)

          2. 25 Subjects will have transplant vasculopathy and 25 subjects will be free of
             transplant vasculopathy, as documented in previous angiograms.

          3. Otherwise healthy

        Exclusion criteria:

          1. PVC &lt; 30

          2. Hypertensive subjects on ACE inhibitors

          3. Pregnant or nursing mothers

          4. Diabetic with HbA1C &gt; 7.5 or stigmata of end organ damage (neuropathy, retinopathy,
             nephropathy, cardiomyopathy)

          5. Cholesterol &gt; 30 mg/dL above NCEP accepted level based on cardiac risk.

          6. Triglycerides &gt; 200

          7. Previously diagnosed obstructive coronary artery disease

          8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)

          9. History of cerebrovascular disease

         10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)

         11. Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to
             hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal
             insufficiency, prior cerebrovascular disease).

         12. Angiotensin converting enzyme inhibitor use

         13. Coagulopathy (INR ≥ 1.5, PTT ≥ 150% of control)

         14. Peripheral Vascular Disease

         15. Other chronic medical illnesses at the discretion of the investigators

        Healthy controls are being enrolled in SCCOR Project 1, Aims 3A and 3B (IRB# 030473 and
        061160) and will not be participating under this IRB number.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A S AS Muldowney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>James Muldowney</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Heart Transplant</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>Resting conditions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

